Skip to main content
SYNLAB AG logo

SYNLAB AG — Investor Relations & Filings

Ticker · SYAB ISIN · DE000A2TSL71 LEI · 984500883BA5AQ14C037 F Human health and social work activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2023-10-02 Director's Dealing
Country DE Germany
Listing F SYAB

About SYNLAB AG

https://www.synlab.com/

SYNLAB AG is a leading provider of medical laboratory diagnostic services. The company offers a comprehensive portfolio of over 5,000 routine and specialty tests across various medical disciplines, including human genetics and anatomical pathology. Its services provide essential diagnostic information for doctors, clinics, and patients, playing a vital role in clinical decision-making throughout the entire patient care process, from prevention and diagnosis to treatment and monitoring.

Recent filings

Filing Released Lang Actions
SYNLAB AG: Ebsworth GmbH, sell
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details a transaction (Disposal) made by a "person closely associated" with a member of the administrative body (Prof. Dr. David Ebsworth) of SYNLAB AG. This directly matches the definition for Director's Dealing reports.
2023-10-02 English
SYNLAB AG: SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven
M&A Activity Classification · 99% confidence The document is a press release dated September 29, 2023, announcing that SYNLAB AG has entered into an investment agreement related to a public acquisition offer by Cinven. Key terms like 'public acquisition offer,' 'investment agreement,' 'shareholders,' and 'Management Board and Supervisory Board will issue their reasoned statement' strongly indicate a significant corporate action related to ownership change or takeover. This type of announcement, detailing a proposed transaction (takeover/acquisition) and the associated agreements, fits best under the M&A Activity category (TAR). It is not a standard financial report (10-K, IR, ER) or a simple announcement of a report (RPA).
2023-09-29 English
SYNLAB AG: Cinven announces public acquisition offer | Conclusion of Investment Agreement
M&A Activity Classification · 98% confidence The document is an 'Ad-hoc' announcement dated September 29, 2023, disclosing inside information under MAR Regulation (EU) No 596/2014. The core content details that Cinven announced a public acquisition offer for SYNLAB AG shares and concluded an Investment Agreement. This clearly relates to a takeover bid or merger proposal. Based on the definitions, the category 'M&A Activity (Code: TAR)' is the most appropriate fit for announcements related to merger proposals or takeover bids.
2023-09-29 English
Half-yearly financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Financial Report' for SYNLAB AG for the period ending 30 June 2023. It contains comprehensive financial statements (P&L, cash flow, balance sheet), management discussion and analysis, and notes to the financial statements. It is a full interim report, not an announcement or a summary, and therefore fits the definition of an Interim / Quarterly Report (IR). H2 2023
2023-08-17 English
SYNLAB AG: SYNLAB agrees to sell its veterinary diagnostics business to Mars
M&A Activity Classification · 99% confidence The document is a press release dated August 14, 2023, announcing that SYNLAB AG has agreed to sell its veterinary diagnostics business to Mars Incorporated. It uses keywords like 'Press Release', 'Strategic Company Decision/Disposal', and details a significant corporate transaction (divestiture). This type of announcement, detailing a major strategic move like a sale or acquisition, does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). It is a significant corporate event announcement. Since it is not a standard regulatory filing like a 10-K or a specific financial report, and it details a major transaction, it is best classified as a general Regulatory Filing (RNS) as it is disseminated via EQS News, which explicitly mentions handling 'Regulatory Announcements' and 'Financial/Corporate News'. It is not a M&A proposal (TAR) but a completed agreement to sell a division, which often falls under general corporate news.
2023-08-14 English
SYNLAB AG: Continued strong performance in the second quarter of 2023
Earnings Release Classification · 100% confidence The document is titled 'SYNLAB AG: Continued strong performance in the second quarter of 2023' and explicitly states it announces its 'auditor-reviewed Q2/H1 2023 results.' It contains detailed financial tables covering Q2 and H1 performance, including revenue, Adjusted EBITDA, and cash flow. The text also mentions the 'Half-Year Financial Report 2023 is available for download.' Since this document provides the comprehensive financial results for a period shorter than a year (H1 2023), it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report (RPA) because it contains the full results summary and tables, and its length (over 21,000 characters) suggests it is the primary reporting document, not just a brief notice. H1 2023
2023-08-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.